Methods for predicting response to HDACi/DNMTi combination in multiple myeloma

摘要

The present invention relates to a method of testing whether a patient suffering from multiple myeloma will respond or not to a combination treatment consisting of at least one histone deacetylase inhibitor (HDACi) with at least one DNA methyltransferase inhibitors (DNMTi) comprising: i) determining the expression level (ELi) of several genes G₁-G_n selected from table A in a biological sample obtained from said patient ii) comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HADMS score trough the following formula (I) wherein βi represent the regression β coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=−1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score HADMS determined at step iii) with a predetermined reference value HADMS_R v) and concluding that the patient will respond to the combination treatment when the HADMS score is higher than the predetermined reference value HADMS_R or concluding that the patient will not respond to the combination treatment when the HADMS score is lower than the predetermined reference value HADMS_R.; $$ \begin{array}{cc}H\&\#x2062;\&\#x2062;A\&\#x2062;\&\#x2062;D\&\#x2062;\&\#x2062;M\&\#x2062;\&\#x2062;S=\underset{i=1}{\overset{n}{\&\#x2211;}}\&\#x2062;\beta \&\#x2062;\&\#x2062;i\times \mathrm{Ci}& \left(I\right)\end{array}$$